Prostate cancer gene therapy

Hematology/Oncology Clinics of North America

Volumn 15, Issue 3, 2001, Pages 497-508

  Ferrer, F A ^a   Rodriguez, R ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; GENE THERAPY; HUMAN; IMMUNOSTIMULATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0034889084     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70228-8     Document Type: Article

References (32)

1. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
2. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
3. Retrovirade and their replication
4. CD28/B7 costimulation: A review
5. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer
6. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
7. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
8. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
9. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors
10. Gene therapy with physical methods of gene transfer
11. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients
12. Urologic applications of gene therapy
13. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics
14. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
15. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
16. MHC antigens on human tumors
17. Dendritic cell-based immunotherapy of prostate cancer
18. Molecular characterization of defective antigen processing in human prostate cancer
19. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
20. Peptide and carbohydrate vaccines in relapsed prostate cancer: Immunogenicity of synthetic vaccines in man-clinical trials at Memorial Sloan-Kettering Cancer Center
21. Antisense c-myc retroviral vector suppresses established human prostate cancer
22. Origin and general nature of retroviruses
23. Dendritic cell vaccines for cancer immunotherapy
24. Gene therapy using adenoviral vectors
25. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
26. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
27. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
28. Dendritic cell vaccines for cancer immunotherapy
29. Gene therapy using adenoviral vectors
30. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
31. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
32. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts